Teva Rejected by U.S. High Court Justice on Copaxone Patent

A U.S. Supreme Court justice refused to block a ruling that would open Teva Pharmaceutical Industries Ltd.’s Copaxone multiple-sclerosis drug to generic competition in May.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.